COMMERCIALISATION

CIMR COMMERCIALISATION PROJECTS:

CIMR has partnered with Celestino Pty Ltd to change the way Australia does science.

Celestino is an Australian owned family business and member of the Baiada Group which is renowned for iconic brands, such as Steggles and Lilydale Chickens, founded in 1916.

Since 2009, Celestino has been working on the master-planning, visioning and rezoning of key development projects including the multibillion-dollar Sydney Science Park greenfield development located 3 km’s north of the planned Western Sydney Airport.

Celestino and CIMR recognise the opportunity to provide world leading medical & health translational programs and facilities to meet the needs of a growing population and economic activity that will be catalysed by the planned Western Sydney Airport and the surrounding Western Sydney Aerotropolis.

Therefore, to facilitate the CIMR objectives and the vision of Celestino, CIMR has joined forces with Celestino to create an internationally recognised epicentre for research and development at the Sydney Science Park. Watch this space as our SSP project develops over the coming months.

Innovatio Pty Ltd was established in 2021 as a start up company (the first spin out from CIMR), which holds the IP rights to the preeclampsia diagnostic test developed by Dr Lana McClements from UTS.

Preeclampsia is a devastating cardiovascular disease in pregnant women and the single large cause of fatality of both the mother and baby. It is crucial that this condition is detected early on in the pregnancy so that the effected woman is carefully monitored and treated for the accompanying physiological problems such as high blood pressure.

The diagnostic test developed relies on two biomarkers (FKBPL and CD44) which undergo changes in relative amounts (ratio) during pregnancy. The FKBPL/CD44 ratio can accurately predict early onset preeclampsia from 20-weeks of pregnancy onwards. Innovatio owns the two patents that are currently pending in the USA, Europe and Australia.

Thus far, several hundred clinical samples from women in the USA, Ireland and Serbia have been tested and the results have been very promising in terms of the accuracy of the ELISA test. Recently, a point of care test has also been developed using these two biomarkers and the results thus far have been excellent with an accuracy of over 90%.

Innovatio is now looking for a corporate partner to complete the development of a validated product that can be taken to the global market and start helping women from all over the world to be able to monitor their health during pregnancy. If you feel you could help us with these next steps, please contact us.

The Coeliac disease diagnostic test was developed as a result of a student project that came out of the Innovation, Entrepreneurship and Commercialisation course run annually at UTS. This project highlights the value of both the educational programs that CIMR runs as well as its capability in translating early stage research.

The idea was created by a small group of students, two of which (Dr Anantdeep Kaur and Ms Buket Demirci) decided to try and develop the idea into a translatable product. In order to do so, Dr Kaur was able to enlist the support of Dr Olga Shimoni and Professor Michael Wallach who became her supervisors in carrying out her Honours and PhD project. Over the period of PhD work, Dr Kaur was able to demonstrate that using gold nanoparticles coated with the key autoimmune inducing wheat antigen, Gliadin, she was able to develop a test with over 90% accuracy in detecting Coeliac disease from clinical samples of both blood and saliva.

The results of this work has been published in prestigious journals and is currently seeking an industry partner to take it to the market. If you feel you could help us with these next steps, please contact us.

CIMR is not only committed to new ideas and education, but also to establishing environments in which healthcare research and commercialisation can flourish.

COMMERCIALISATION

CIMR COMMERCIALISATION PROJECTS:

Tel: +61 (0) 412 009 333 Email: info@cimrglobal.com Sydney, Australia

Tel: +61 (0) 412 009 333
Email: info@cimrglobal.com
Sydney, Australia